title: A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
abstract: Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sézary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed.
authors.affiliation: Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19146, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Gardner
authors.forename: Camille E
authors.initials: CE
authors.lastname: Introcaso
authors.forename: Sunita D
authors.initials: SD
authors.lastname: Nasta
authors.forename: Ellen J
authors.initials: EJ
authors.lastname: Kim
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D000077337:Vorinostat
chemical_list: D006877:Hydroxamic Acids; D000077337:Vorinostat; D007371:Interferon-gamma